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Summary
Background: Inﬂammation is a critical contributing factor to the development and progression
of atherosclerosis. Pentraxin 3 (PTX3) is produced abundantly in atherosclerotic lesions while
C-reactive protein (CRP) is mainly produced in the liver. In this study, we investigated whether
plasma levels of PTX3 might be a sensitive marker both for the severity of coronary artery dis-
ease and vulnerable plaques. Next, we determined whether assays for inﬂammatory molecules
can be used to monitor the therapeutic effects of telmisartan on stabilization of vulnerable
atherosclerotic plaques.
Methods and results: We measured PTX3 concentrations in the peripheral and coronary sinus
plasma of 40 patients with angina pectoris (AP) and 20 control subjects. Next, in 28 patients
with AP, we determined the correlation between levels of inﬂammatory molecules and the com-
puted tomography (CT) density of plaques as a quantitative index of plaque vulnerability. There
was no signiﬁcant difference in peripheral plasma PTX3 concentrations between patients with
AP and control subjects, while coronary sinus plasma PTX3 concentrations were signiﬁcantly
higher in AP patients than control subjects. The concentrations of PTX3 in coronary sinus and
peripheral plasma correlated with Gensini scores as an index of severity of coronary atheroscle-
rosis. Interestingly, there was a signiﬁcantly negative correlation between plasma PTX3
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concentrations and CT density (r =−0.67, p < 0.01). On the other hand, CT density did not corre-
late with the peripheral plasma concentrations of monocyte chemoattractant protein-1 (MCP-1)
or high-sensitivity CRP (hsCRP). Furthermore, telmisartan treatment for 6 months decreased
plasma concentrations of PTX3 but not those of MCP-1 or hsCRP in 12 patients with essential hyper-
tension. Multivariate regression analysis revealed that changes in PTX3 levels were independent
of blood pressure changes.
Conclusions: PTX3 is likely more speciﬁc than hsCRP as an indicator of coronary plaque vulner-
que rupture.
ardiology. Published by Elsevier Ltd. All rights reserved.
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linked immunosorbent assay, using the F(ab′)2 fragment of a
monoclonal anti-human PTX3 antibody, PPMX0104 (Perseus
Proteomics Inc., Tokyo, Japan) as the capture antibodyability that could lead to pla
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nﬂammation is a critical contributing factor to the devel-
pment and progression of atherosclerosis, which represents
he primary cause of ischemic heart disease and stroke [1,2].
variety of inﬂammatory and other biochemical mark-
rs potentially related to atherogenesis has been identiﬁed
3,4]. However, few inﬂammatory markers are recognized
s established measures of cardiovascular risk prediction.
-reactive protein (CRP) is one of the most actively studied
iomarkers. The association between elevated CRP levels
nd an increased risk for developing cardiovascular events
s well established [5]. However, CRP response is triggered
y many disorders unrelated to cardiovascular disease.
Pentraxin 3 (PTX3) is the prototypic member of the long
entraxin family and has C-terminal sequence homology
ith the classic short pentraxins CRP and serum amy-
oid P component. PTX3 is produced abundantly by various
ells in atherosclerotic lesions, including monocytes and
acrophages, endothelial cells, vascular smooth muscle
ells, ﬁbroblasts, dendritic cells, and adipocytes, while CRP
s mainly produced in the liver [6]. These ﬁndings suggest
hat plasma PTX3 concentration reﬂects local inﬂammation
t the site of the atherosclerotic lesion itself.
In the present study, we compared the roles of plasma
TX3 levels and CRP levels as sensitive markers for
he severity of coronary artery disease, evaluated using
oronary angiography, and vulnerable plaque, assessed
y multidetector-row computed tomography (MDCT). In
ddition, we determined whether assays of inﬂammatory
olecules can be used to monitor the therapeutic effect of
elmisartan—–which has been shown to modulate endothe-
ial inﬂammation and oxidative cell damage in vitro [7]—–on
tabilization of vulnerable atherosclerotic plaques.
ethods
atients
tudy 1
e studied 40 patients with stable angina pectoris (AP)
mean age: 69 years) and 20 control subjects who had
o coronary artery stenosis on angiography (mean age: 68
ears). All patients in the control group had no evidence of
eart failure or no abnormality in echocardiogram. AP was
eﬁned as the occurrence of typical chest pain only dur-
ng physical exertion and relieved by rest or nitroglycerine
nd stenosis of more than 50% of the vessel diameter on
a
h
a
tlective coronary angiogram. Patients diagnosed as having
nstable angina who underwent emergency coronary angiog-
aphy with recent change in the character, frequency, or
everity of anginal pain were excluded. All patients gave
ritten informed consent prior to participation in the study.
The results of coronary angiography were interpreted
y 2 senior angiographers who had no knowledge of the
esults of the biochemical analysis. Based on the primary
ngiographic results (before coronary intervention), we
alculated the Gensini score [8] as the index of the sever-
ty of coronary atherosclerosis and subsequently examined
he correlation between plasma PTX3 concentrations and
ensini scores.
Blood samples were obtained both from the periphery
nd from the coronary sinus just before coronary angiogra-
hy.
tudy 2
e studied 28 patients (mean age: 67 years) with AP who
nderwent MDCT (Aquilion, Toshiba Medical, Tokyo, Japan)
hat showed coronary atherosclerotic plaque.
Blood samples were obtained from the periphery just
efore MDCT. We investigated whether plasma levels
f inﬂammatory molecules, including PTX3, monocyte
hemoattractant protein-1 (MCP-1), and high-sensitivity C-
eactive protein (hsCRP), were sensitive markers for the
ulnerable plaque characterized by MDCT.
tudy 3
ext, we determined whether assays for inﬂammatory
olecules including PTX3 can be used to monitor the ther-
peutic effect of telmisartan—–which has been shown to
odulate endothelial inﬂammation in vitro—–on stabiliza-
ion of vulnerable atherosclerotic plaques in 12 patients with
ssential hypertension (mean age: 69 years). As the con-
rol group, 8 patients receiving the calcium channel blocker,
mlodipine, were also studied.
iochemical analysis
lasma concentrations of PTX3 were measured by enzyme-nd PPMX0105 (Perseus Proteomics Inc.) conjugated with
orseradish peroxidase as the detection antibody, based on
previously described method [9]. Plasma MCP-1 concen-
rations were determined by enzyme-linked immunosorbent
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Table 1 Patient characteristics.
Angina pectoris Control
n 40 20
Age (years) 69± 9 68± 9
Male/female 27/13 12/8
Smoking (n) 17 (43%) 5 (25%)
Hypertension (n) 24 (60%) 8 (40%)
Diabetes mellitus (n) 14 (35%) 3 (15%)
LDL-C (mg/dl) 127± 33 121± 33
HDL-C (mg/dl) 47± 12 54± 13
Triglycerides (mg/dl) 138± 52 120± 50
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol.
assay (R&D Systems, Abingdon, UK). Serum hsCRP concen-
trations were measured by the latex agglutination method.
MDCT images (Study 2)
MDCT was performed immediately after the blood sampling
using an Aquilion Advanced Multidetector-row CT, based on
a previously described method [10]. An experienced cardi-
ologist and an experienced radiologist evaluated coronary
CT scans. Curved and cross-sectional images of coronary
artery wall plaques were obtained, and CT values were
measured using circular regions of interests (ROIs) on the
cross-sectional multiplanar reconstruction (MPR) images. In
Figure 1 Plasma pentraxin 3 (PTX3) concentrations in the
periphery and coronary sinus of control subjects and patients
with angina pectoris (AP). There was no signiﬁcant difference
in peripheral plasma PTX3 concentrations between AP patients
and control (top). Plasma PTX3 concentrations in the coronary
sinus were higher in patients with AP than in control subjects
(bottom).
Figure 2 Plasma pentraxin 3 (PTX3) concentrations and
coronary atherosclerosis. Peripheral plasma PTX3 concentra-
tions were signiﬁcantly correlated with Gensini scores (top). A
s
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ptronger correlation was seen between Gensini scores and the
oncentrations of PTX3 in coronary sinus plasma (bottom).
P patients who hadmultiple plaques in the culprit segment,
he minimum CT value of the plaque at the stenotic lesion
as used for analysis.
dministration of telmisartan (Study 3)
elmisartan was prescribed once per day at a dose of 40mg
mmediately after breakfast for 6 months. The target sys-
olic/diastolic blood pressure was <130/85mmHg in patients
nder 74 years old. In those over age 75 years, the target
lood pressure was 140/90mmHg. In patients in whom the
ystolic/diastolic blood pressure did not reach the target
lood pressure, the telmisartan dose was increased to 80mg.
efore and after telmisartan administration, biochemical
nalysis (PTX3, MCP-1, hsCRP) was performed.
tatistical analysis
alues are expressed as the means± S.D. Comparisons
etween two groups were performed using a Student’s
npaired t-test for continuous variables and a chi-square
est for categorical variables. Correlations between two
arameters were assessed using simple linear regression.
154 T. Soeki et al.
Figure 3 Correlation between computed tomography (CT) density and peripheral plasma pentraxin 3 (PTX3) concentrations.
Peripheral plasma PTX3 concentrations negatively correlated with CT density (top). In contrast, no correlation was seen between
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esults
atient characteristics
able 1 summarizes the characteristics of each study group.
here were no signiﬁcant differences in age, gender, inci-
ence of smoking, hypertension, diabetes, or levels of
ow-density lipoprotein cholesterol, high-density lipoprotein
holesterol, or triglycerides between AP patients and con-
rols. The lesion site of coronary artery disease was the left
nterior descending artery in 23 patients (57.5%), left cir-
umﬂex artery in 12 cases (30.0%), and right coronary artery
n 19 (47.5%).
lasma PTX3 concentrations and coronary
therosclerosis
here was no signiﬁcant difference in peripheral plasma
TX3 concentrations between AP patients and controls
2.6± 1.0 ng/ml vs. 2.1± 0.7 ng/ml) (Fig. 1, top). Coronary
inus plasma PTX3 concentrations were higher in AP patients
han in control subjects (2.8± 1.3 ng/ml vs. 2.1± 0.8 ng/ml)
Fig. 1, bottom).
PTX3 concentrations in peripheral plasma signiﬁcantly
orrelated with Gensini scores (r = 0.32, p < 0.05) (Fig. 2,
op). This correlation was even stronger for PTX3 in coronary
inus plasma (r = 0.46, p < 0.01) (Fig. 2, bottom). Further-
ore, there was more strong correlation between the delta
a
p
h
lmoattractant protein-1 (MCP-1) or high-sensitivity C-reactive
TX3 (coronary sinus PTX3 — peripheral PTX3) and Gensini
core (r = 0.49, p < 0.01).
orrelation between CT density and peripheral
lasma PTX3 concentrations
here was a signiﬁcantly negative correlation between
lasma PTX3 concentrations and CT density (r =−0.67,
< 0.01) (Fig. 3, top). On the other hand, peripheral plasma
oncentrations of MCP-1 and hsCRP did not correlate with
T density (NS) (Fig. 3, bottom).
hanges in plasma levels of inﬂammatory markers
efore and after 6 months of telmisartan treatment
he pretreatment systolic and diastolic blood pressures
ere 152± 9 and 90± 6mmHg, respectively. After telmis-
rtan administration, these decreased signiﬁcantly to
37± 9 and 79± 6mmHg, respectively (p < 0.01) (Fig. 4).
lasma PTX3 concentrations decreased signiﬁcantly from
.75± 0.95 ng/ml to 2.06± 0.58 ng/ml after telmisartan
reatment (p < 0.05) (Fig. 4). On the other hand, plasma con-
entrations of MCP-1 and hsCRP did not change following
elmisartan administration (Fig. 4). Multivariate regression
nalysis revealed that changes in PTX3 levels were inde-
endent of variations in blood pressure, lipid proﬁles, and
emoglobin A1c levels. While comparable blood pressure
owering was achieved in patients treated with amlodip-
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Figure 4 Changes in plasma levels of inﬂammatory markers before and after 6 months of telmisartan treatment. After telmisartan
administration, both systolic and diastolic blood pressures were signiﬁcantly decreased (p < 0.01). Plasma concentrations of pentraxin
3 (PTX3) decreased signiﬁcantly from 2.75± 0.95 ng/ml to 2.06± 0.58 ng/ml after telmisartan treatment (p < 0.05). On the other
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not change with telmisartan administration.
ine (from 154± 9/91± 6mmHg to 140± 7/81± 6mmHg),
plasma concentrations of PTX3, MCP-1 and hsCRP did not
change after the administration of amlodipine.
Discussion
In the present study, we demonstrate the direct relationship
between plasma PTX3 concentrations and coronary plaques.
Furthermore, we report that the plasma PTX3 level may be
a sensitive marker for vulnerable plaques.
Our ﬁndings agree with previous basic and clinical
research. We found that PTX3 concentrations in coronary
sinus plasma or delta PTX3 correlated with Gensini scores
more strongly than those in peripheral plasma, suggest-
ing that PTX3 reﬂects the degree of local inﬂammation
in coronary atherosclerosis; it also agrees with previous
basic research in which immunohistochemistry of advanced
atherosclerotic lesions showed an elevated PTX3 expression
in neutrophils and macrophages [11,12] and with clinical
studies demonstrating that patients with acute myocardial
infarction and unstable angina had elevated plasma PTX3
concentrations [9,13].
Interestingly, peripheral plasma PTX3 concentrations
strongly correlated with CT density, while MCP-1 and hsCRP
concentrations did not. A previous report showed that MDCT
can detect coronary artery plaques by demonstrating good
agreement between the CT density of plaques and their
t
p
c
u-1 (MCP-1) and high-sensitivity C-reactive protein (hsCRP) did
chogenicity as determined by intracoronary ultrasound;
ow-density plaques on CT correspond to lipid core-
ontaining coronary plaques, while medium-density plaques
orrespond to ﬁbrous coronary plaques [14]. Another pre-
ious study showed that patients with acute coronary
yndrome had low-density plaques on CT as compared with
hose shown in patients with stable angina, and that plaque
ensity was lower in culprit segments than in non-culprit
egments in patients with acute coronary syndrome [15].
hus, MDCT may potentially predict future cardiac events.
hese ﬁndings, together with our results, suggest that
lasma PTX3 concentrations reﬂect coronary plaque vulner-
bility that leads to plaque rupture more speciﬁcally than
RP or MCP-1 concentrations.
In the present study, the concentrations of neither hs-
RP nor MCP-1 were correlated with plaque density on CT,
uggesting that CRP and MCP-1 may be relatively poor pre-
ictors of vulnerable plaques in comparison with PTX3. This
nding does not agree with previous large-scale studies
hat showed CRP as a strong and independent predictor of
therosclerotic risk in individuals with and without estab-
ished cardiovascular disease [16]. CRP likely reﬂected other
ystemic inﬂammation such as transient infection, and the
esulting overestimation could have a signiﬁcant effect on
he speciﬁcity of CRP for evaluating vulnerable coronary
laques in a limited number of patients. Plasma MCP-1 con-
entrations were reported to be higher in patients with
nstable angina than those with stable angina [17]. While
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CP-1 mediates monocyte recruitment and entry into ves-
el walls at sites of atherosclerosis, PTX3 is associated with
acrophage differentiation into foam cells and with neu-
rophil inﬁltration into atherosclerotic plaques [12]; these
ifferences might lead to the result of our study showing
hat PTX3 was more speciﬁcally related to plaque instabil-
ty than MCP-1. Neutrophils as well as foamy macrophages
ave been shown to be major sources of PTX3, contributing
o the process of coronary atherosclerotic plaque activation
12] and potentially leading to plaque rupture, thrombosis,
nd ischemia.
It has been demonstrated that the inhibition of the
enin—angiotensin system by an angiotensin-converting
nzyme inhibitor or an angiotensin II receptor type 1 antag-
nist reduces cardiovascular disease [18,19]. In particular,
elmisartan has been shown to have peroxidase proliferator-
ctivated receptor gamma activating effects independent
rom its angiotensin II-receptor blocking abilities [20] and
s suggested to improve insulin sensitivity, leading to a
eduction of the risk for atherosclerosis. In addition, our
ecent study showed that telmisartan decreased pulse-wave
elocity [21], suggesting that this agent improves vascu-
ar endothelial function. However, there has not been a
oncise and speciﬁc biomarker that reﬂects the degree of
therosclerosis and the effect of pharmacologic intervention
n the same way, for instance, that brain natriuretic peptide
eﬂects the degree of heart failure. Therefore, we investi-
ated whether telmisartan decreased the level of PTX3 and
hether PTX3 level is a surrogate marker for atheroscle-
osis. In the present study, we showed that plasma PTX3
oncentrations decreased signiﬁcantly after treatment with
elmisartan and changes in PTX3 levels were independent
f blood pressure changes, suggesting that PTX3 is likely
useful marker for monitoring the anti-plaque effect of
elmisartan.
Our study has several limitations. First, our sample size
as small. We measured the plasma concentrations of PTX3,
CP-1, and hsCRP in only a limited number of patients, and
ere therefore unable to deﬁnitively exclude the predic-
ive value of MCP-1 and hsCRP regarding vulnerable plaques.
econd, we used only MDCT for the evaluation of coronary
ulnerable plaques. To conﬁrm the relationship between
TX3 and vulnerable plaques, in further studies we should
se other examination methods for coronary vulnerable
laques, such as intracoronary ultrasound. Third, we did not
erform sampling from coronary sinus in Study 2 because
he different timings of MDCT and sampling from coronary
inus (at coronary angiography) may have some effects on
he results.
In conclusion, we found that there was a signiﬁcantly
egative correlation between plasma PTX3 concentrations
nd CT density, but no correlation between CT density and
lasma concentrations of MCP-1 and hsCRP. Thus, PTX3 likely
eﬂects coronary plaque vulnerability that leads to plaque
upture more speciﬁcally than MCP-1 or CRP.
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